BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23448270)

  • 1. Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
    Carlsson SV; Peltola MT; Sjoberg D; Schröder FH; Hugosson J; Pettersson K; Scardino PT; Vickers AJ; Lilja H; Roobol MJ
    BJU Int; 2013 Sep; 112(5):602-9. PubMed ID: 23448270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
    Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
    Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
    Braun K; Sjoberg DD; Vickers AJ; Lilja H; Bjartell AS
    Eur Urol; 2016 Mar; 69(3):505-11. PubMed ID: 25979570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
    Vickers AJ; Cronin AM; Roobol MJ; Savage CJ; Peltola M; Pettersson K; Scardino PT; Schröder FH; Lilja H
    Clin Cancer Res; 2010 Jun; 16(12):3232-9. PubMed ID: 20400522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
    Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M
    Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
    Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
    Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
    Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
    Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
    Vickers A; Cronin A; Roobol M; Savage C; Peltola M; Pettersson K; Scardino PT; Schröder F; Lilja H
    J Clin Oncol; 2010 May; 28(15):2493-8. PubMed ID: 20421547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
    Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
    Assel M; Sjöblom L; Murtola TJ; Talala K; Kujala P; Stenman UH; Taari K; Auvinen A; Vickers A; Visakorpi T; Tammela TL; Lilja H
    Eur Urol Focus; 2019 Jul; 5(4):561-567. PubMed ID: 29137895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
    Vickers AJ; Wolters T; Savage CJ; Cronin AM; O'Brien MF; Pettersson K; Roobol MJ; Aus G; Scardino PT; Hugosson J; Schröder FH; Lilja H
    Eur Urol; 2009 Nov; 56(5):753-60. PubMed ID: 19682790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore.
    Lee A; Lim J; Gao X; Liu L; Chia SJ
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e348-e355. PubMed ID: 27641069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
    Benchikh A; Savage C; Cronin A; Salama G; Villers A; Lilja H; Vickers A
    BMC Cancer; 2010 Nov; 10():635. PubMed ID: 21092177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
    Vickers AJ; Cronin AM; Aus G; Pihl CG; Becker C; Pettersson K; Scardino PT; Hugosson J; Lilja H
    Cancer; 2010 Jun; 116(11):2612-20. PubMed ID: 20336781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
    Stattin P; Vickers AJ; Sjoberg DD; Johansson R; Granfors T; Johansson M; Pettersson K; Scardino PT; Hallmans G; Lilja H
    Eur Urol; 2015 Aug; 68(2):207-13. PubMed ID: 25682340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of the risk of harboring prostate cancer by a prebiopsy nomogram based on extended biopsy protocol.
    Nicolaiew N; Ploussard G; Chun FK; Xylinas E; Allory Y; Salomon L; de la Taille A
    Urol Int; 2013; 90(3):306-11. PubMed ID: 23295308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.
    Vickers AJ; Cronin AM; Aus G; Pihl CG; Becker C; Pettersson K; Scardino PT; Hugosson J; Lilja H
    BMC Med; 2008 Jul; 6():19. PubMed ID: 18611265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relationship between screening by stratifying cases into groups on prostate specific antigen level and the positive rate of transrectal ultrasound guided systematic sextant prostate biopsy].
    Cao XL; Gao JP; Han G; Tang J; Hong BF
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):372-5. PubMed ID: 16638344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort.
    Lonergan PE; Vertosick EA; Assel M; Sjoberg DD; Haese A; Graefen M; Boorjian SA; Klee GG; Cooperberg MR; Pettersson K; Routila E; Vickers AJ; Lilja H
    BJU Int; 2021 Aug; 128(2):218-224. PubMed ID: 33306251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.